Policies to Impact: September 2022

Welcome to the monthly newsletter from the Global Healthcare Alliance Accelerator (GHIAA)! You can also? join our quarterly newsletter for a round-up of news delivered straight to your inbox, as well as following us on LinkedIn and Twitter for daily updates.?

Questions? We’d love to hear from you at [email protected].

• On September 14, Julie participated in a panel discussion, Creating Sustainable Infrastructure for Pandemic Preparedness and Response, hosted by the The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School . Julie spoke alongside participants from The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, the Harvard University Kennedy School of Government, Ginkgo Bioworks, Inc., and University of Massachusetts Lowell. ?(A video recording of the panel discussion will be available here.)

• On September 23, Julie spoke at the Global Health Law Course convened by the Singapore Ministry of Foreign Affairs’ Cooperation Program, in conjunction with the 新加坡国立大学 Centre for International Law.

The events we participate in are not always open to the public, but we invite you to join us and learn more about our participation whenever possible:

• GHIAA Board member Ana Santos Rutschman will be presenting “The Role of Intellectual Property in Achieving Global Health Security” at the World Intellectual Property Forum in Bangkok on October 12, 2022, 9:00am local time. View the full agenda here.?
• On October 18, 2022 at 2:15 PST, Julie will moderate a panel session at the Licensing Executives Society (U.S.A. and Canada), Inc. (LES) Annual Meeting entitled, “Working with Funders and International Organizations to Access Non-Traditional Global Markets.” The panel will feature Katrine Thor Andersen, MBA , GHIAA board member, Andrew Spencer Goldman , general counsel and head of policy at Roivant Social Ventures , and Sandra Nobre , Head of Global Business Development at the Medicines Patent Pool .

We frequently update the MAPGuide? with new agreements and provisions. We welcome you to contribute your own agreements here; we accept anonymized and redacted content, as well as template and model agreements. Some of our latest additions include:

• Alnylam Pharmaceuticals - University of British Columbia- AlCana Technology, Sponsored Research Agreement: This agreement between Alnylam Pharmaceuticals , Inc., a publicly traded biopharmaceutical firm, the The University of British Columbia and AlCana Technologies, Inc., a private biotechnology company (now known as Acuitas Therapeutics ) governs a joint research program related to the delivery of oligonucleotides (i.e., lipid-based, synthetic RNA/DNA delivery). Under the agreement, Alnylam must use commercially reasonable efforts to develop and commercialize licensed products, as well as making milestone payments and paying royalties. If Alnylam develops a licensed product for a therapeutic intervention that addresses a disease afflicting a significant portion of the population in low income or lower middle income countries, then it must use commercially reasonable efforts to commercialize that product in a manner consistent with UBC’s Global Access Principles.
• AXA Prime Impact Master Fund - Revelation Biosciences, Diagnostics & Therapeutics for Viral Infections, Global Health Agreement: This between AXA Prime Impact Master Fund and Revelation Biosciences Inc. , was signed in December 2020 in connection with AXA’s purchase of shares in Revelation Biosciences totalling approximately USD $4 million. The key purposes of AXA’s investment are to provide relief and improvements to health in low- or lower-middle-income countries, and to educate health practitioners and public officials on cost-effective technologies designed to improve the health and safety of individuals globally. Under the agreement, Revelation Biosciences agrees to make specified products? available at an affordable price to non-profit organizations and public sector purchasers in target countries, and to meet the product supply requirements of those purchasers.?

• The Lancet Commission on lessons for the future from the COVID-19 pandemic, Published Online, September 14, 2022. https://doi.org/10.1016/S0140-6736(22)01585-9; See Online/Editorial https://doi.org/10.1016/S0140-6736(22)01761-5?
• Four Approaches to Supporting Equitable Research Partnerships by Garry Aslanyan, Alice Chadwick El-Ali, Maggy Heintz, Eva Kagirl-Kalanzi, John Kirkland, Yaso Kunaratnam, Sheila Mburu, Tolu Mohammed, Amen-Patrick Nwosu, Laura Scott and Daniela Toale for UKCDR and ESSENCE.
• Funding Sources of Therapeutic and Vaccine Clinical Trials for COVID-19 vs Non-COVId-19 Indications, 2020-2021, by Aris Angelis, PhD1,2; Carlos Suarez Alonso, MSc1,2; Ilias Kyriopoulos, PhD2; et al in JAMA Network Open.
• Opinion: Unprepared for the Big One by Seth Berkley (GAVI) in POLITICO